1. CLINICAL OUTCOMES OF DIFFERENT SUBTYPES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DURING AFLIBERCEPT TREATMENT
- Author
-
Magdalena Baratsits, Ursula Schmidt-Erfurth, Sandra Rezar-Dreindl, Katia Maccora, Wolf Buehl, Katharina Eibenberger, Stefan Sacu, and Sebastian M Waldstein
- Subjects
Male ,medicine.medical_specialty ,Visual acuity ,genetic structures ,Fundus Oculi ,Recombinant Fusion Proteins ,Visual Acuity ,Angiogenesis Inhibitors ,Retinal Pigment Epithelium ,chemistry.chemical_compound ,Atrophy ,Ophthalmology ,medicine ,Humans ,Fluorescein Angiography ,Aged ,Retrospective Studies ,Aflibercept ,business.industry ,Retinal ,General Medicine ,Diabetic retinopathy ,Macular degeneration ,medicine.disease ,eye diseases ,Confidence interval ,Receptors, Vascular Endothelial Growth Factor ,Treatment Outcome ,Choroidal neovascularization ,chemistry ,Intravitreal Injections ,Wet Macular Degeneration ,Female ,sense organs ,medicine.symptom ,business ,Tomography, Optical Coherence ,medicine.drug - Abstract
Purpose To prospectively evaluate the outcomes of different subtypes of neovascular age-related macular degeneration during intravitreal aflibercept monotherapy. Methods Forty-four eyes of 44 patients with treatment-naive polypoidal choroidal vasculopathy (PCV, n = 12), hemorrhagic choroidal neovascularization (hCNV, n = 12), pigment epithelium detachment (PED, n = 11), or retinal angiomatous proliferation (RAP, n = 9) were included and followed for 12 months. All patients received intravitreal aflibercept monotherapy. Results Mean visual acuity at baseline in PCV was 67 ± 16 Early Treatment Diabetic Retinopathy Study letters (20/50 Snellen equivalent), in hCNV 55 ± 21 (20/80), in RAP lesions 64 ± 11 (20/50), and in PED 74 ± 7 (20/32). At Month 12, visual acuity in PCV was 66 ± 16 (20/50), in hCNV 69 ± 17 (20/40), in RAP 68 ± 12 (20/50), and in PED 69 ± 18 (20/40). At the 12-month follow-up, visual acuity improved or was stable (±5 letters from baseline) in 84% of eyes (37/44 patients), with hCNV showing the greatest mean visual acuity gain. Mean central retinal thickness in patients with PCV was 523 ± 251 µm, in hCNV 497 ± 171, in RAP lesions 573 ± 132, and in PED 541 ± 158 and decreased to 310 ± 91 µm in PCV, 323 ± 75 µm in hCNV, 357 ± 173 µm in RAP lesions, and 422 ± 150 µm in PED. The mean area of atrophy increased from 2.0 ± 3.6 mm2 at baseline to 4.6 ± 8.6 mm2 at Month 12 (mean difference [95% confidence interval] -0.8 [-8.5 to 7.0], P = 0.8), with the greatest atrophy in patients with PED at Month 12. Conclusion All subtypes of neovascular age-related macular degeneration showed anatomical improvement and stabilization of visual function during intravitreal treatment.
- Published
- 2020
- Full Text
- View/download PDF